» Articles » PMID: 28895630

[Changes in OCT Angiography of Type 2 CNV in Neovascular AMD During Anti-VEGF Treatment]

Overview
Publisher Thieme
Specialty Ophthalmology
Date 2017 Sep 13
PMID 28895630
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

OCT-A is a new method to visualise the 2D and 3D structures of neovascular complexes in exudative AMD. The aim of the present study was to characterise type 2 CNV in different 2D segmentations and in 3D imaging and to investigate changes during anti-VEGF treatment. 12 patients with type 2 CNV in FA and SD-OCT were selected. OCT-A (Avanti, Optovue) was obtained initially and after the first three injections and thereafter, if "new activity" (increase in sub- or intraretinal fluid) occurred. The characteristics of the type 2 CNV were classified initially and during follow-up in different segmentations (outer retina, RPE, CC, choroidea), in respect to the size of the CNV, the flow area within the CNV and flow index (% of flow area within the total lesion). Comparison of the vessel characteristics before and after anti-VEGF treatment showed a significant reduction in the size of CNV at every level (p < 0.05). This was most significant at the RPE level (p < 0.005). After new activity, a significant increase in size was only recognised at the CC level (p < 0.05). Similarly, the most significant changes in the flow area were measured at the RPE level before and after treatment (p < 0.01) and at the CC level after new activity (p < 0.05). Demarcation from type 2 CNV of the bordering tissue was much better when activity occurred. OCT-A provides a new opportunity for the assessment of vascular characteristics of type 2 CNV, and quantifies CNV size and vascularisation under anti-VEGF therapy. This may be used in further studies in combination with SD-OCT scans to describe characteristics of this type of CNV under treatment. OCT-A is an additional medical imaging procedure to SD-OCT and FA, but more experience is needed in distinguishing CNV in the active and non-active stages.

Citing Articles

Optical coherence tomography angiography: a review of the current literature.

Javed A, Khanna A, Palmer E, Wilde C, Zaman A, Orr G J Int Med Res. 2023; 51(7):3000605231187933.

PMID: 37498178 PMC: 10387790. DOI: 10.1177/03000605231187933.


Axial Stretching of Vessels in the Retinal Vascular Plexus With 3D OCT-Angiography.

Kuhlmann J, Rothaus K, Jiang X, Heimes-Bussmann B, Faatz H, Book M Transl Vis Sci Technol. 2022; 11(2):21.

PMID: 35147662 PMC: 8844947. DOI: 10.1167/tvst.11.2.21.


Imaging endpoints for clinical trials in MacTel type 2.

Pauleikhoff D, Pauleikhoff L, Chew E Eye (Lond). 2021; 36(2):284-293.

PMID: 34389818 PMC: 8807726. DOI: 10.1038/s41433-021-01723-7.


Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms.

Somasundaran S, Constable I, Mellough C, Carvalho L Clin Exp Ophthalmol. 2020; 48(8):1043-1056.

PMID: 32710488 PMC: 7754492. DOI: 10.1111/ceo.13834.


Progression of vascular changes in macular telangiectasia type 2: comparison between SD-OCT and OCT angiography.

Pauleikhoff D, Gunnemann F, Book M, Rothaus K Graefes Arch Clin Exp Ophthalmol. 2019; 257(7):1381-1392.

PMID: 31093765 DOI: 10.1007/s00417-019-04323-0.